Steatohepatitis/Metabolic Liver Disease News

Researchers observed significant fibrosis in more than one-third of patients with hepatitis B and HIV coinfection undergoing long-term combination antiretroviral therapy with viral suppression, according to a study published in American Journal of Gastroenterology.

Vitamin E supplementation correlated with lower rates of all-cause mortality, liver transplantation and development of hepatic decompensation in patients with nonalcoholic steatohepatitis and advanced fibrosis, according to a study published in Hepatology.

Exemplar Genetics in partnership with Mayo Clinic launched a new company, Cytotheryx, focused on the development of a high-quality source of human liver cells or hepatocytes for clinical research, according to a press release.

Diabetes and high blood glucose levels among individuals without known diabetes correlated with increased risks for liver cancer and chronic liver disease, according results of a Chinese cohort study.

Every year, Healio Gastroenterology and Liver Disease meets with hepatology and gastroenterology experts to discuss their presentations on the latest research data, therapeutic updates, and recent advocacy programs.

Patients with significantly elevated liver iron were more likely men and older and more likely to consume red meat, according to a recently published study.

Bariatric surgery with preoperative very low-calorie diet significantly improved hepatic steatosis in patients with obesity regardless of starting weight or overall weight loss, according to magnetic resonance imaging-estimated proton density fat fraction data from a recently published study.

Akero Therapeutics completed a $70 million Series B financing to support the advancement of the company’s lead clinical candidate, AKR-001, a novel long-acting fibroblast growth 21 analogue for the treatment of nonalcoholic steatohepatitis, according to a press release.

Integral Molecular received $1.4 million from the National Institutes of Health to develop its lead antibodies against cannabinoid receptor 1 for treating nonalcoholic steatohepatitis and metabolic disorders, according to a press release.

ProSciento organized and funded the formation of the “NASH Roundtable,” a collaborative forum of leading academic and clinical developments experts designed to advise drug development programs, according to a press release.